UK Patent Ruling Sharpens Contrast With US Practice

On March 28, 2018, the U.K. Court of Appeal handed down its decision in Regeneron Pharmaceuticals Inc. v. Kymab Ltd. and Novo Nordisk AS,[1] reversing a lower court decision that found...

Already a subscriber? Click here to view full article